Catalysts / RARE
Upcoming FDA decisions and readouts we track for Ultragenyx Pharmaceutical, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Ultragenyx Pharmaceutical (RARE, listed on Nasdaq). It concerns UX111 (Sanfilippo syndrome type A (MPS IIIA)).
First on the list: the PDUFA date for UX111 (Sanfilippo syndrome type A (MPS IIIA)), listed for 19 Sep 2026 by a secondary source, not yet confirmed against the company's own filing.
The row links to a third-party catalyst calendar. It still needs confirming against the company's own filing. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical RARE · Nasdaq | UX111 | Sanfilippo syndrome type A (MPS IIIA) | 19 Sep 2026 18d ago |
PDUFA date | Reported | Catalyst calendar ↗ | Yes |
FreeBioList